Catheter Precision, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
VTAK$0.15-0.7%Stored close · as of Oct 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Product revenue | $270 | $212 | $518 | $355 |
| Service revenue, net | 749 | — | 933 | — |
| Total revenues, net | 1,019 | 212 | 1,451 | 355 |
| Cost of revenues: | ||||
| Cost of product revenue | 22 | 14 | 53 | 25 |
| Cost of service revenue | 899 | — | 910 | — |
| Total cost of revenues | 921 | 14 | 963 | 25 |
| Gross profit | 98 | 198 | 488 | 330 |
| Operating expenses | ||||
| Selling, general and administrative | 3,911 | 2,881 | 6,470 | 6,366 |
| Research and development | 142 | 155 | 291 | 258 |
| Acquired in-process research and development | — | 1,848 | — | 1,967 |
| Total operating expenses | 4,053 | 4,884 | 6,761 | 8,591 |
| Operating loss | (3,955) | (4,686) | (6,273) | (8,261) |
| Other income (expense), net | ||||
| Interest income | 4 | 3 | 6 | 21 |
| Interest expense | (161) | (22) | (237) | (26) |
| Interest expense due to related parties | (43) | (45) | (86) | (90) |
| Change in fair value of royalties payable due to related parties | — | (1,667) | — | (2,830) |
| Change in fair value of trading debt securities | — | 10 | — | 10 |
| Change in fair value of minority equity interest | — | — | (2,302) | — |
| Change in fair value of deferred consideration | 318 | — | 3,195 | — |
| Loss on debt extinguishment | (105) | — | (105) | — |
| Unrealized gains and losses on marketable securities, net | 378 | — | 378 | — |
| Other expenses, net | (54) | (1) | (59) | (1) |
| Total other income (expense), net | 337 | (1,722) | 790 | (2,916) |
| Loss from operations before income tax benefit | (3,618) | (6,408) | (5,483) | (11,177) |
| Income tax benefit | 312 | 950 | 487 | 1,674 |
| Net loss | (3,306) | (5,458) | (4,996) | (9,503) |
| Less: Net loss attributable to non-controlling interest | (11) | (349) | (20) | (349) |
| Net loss attributable to Catheter Precision, Inc. | $(3,295) | $(5,109) | $(4,976) | $(9,154) |
| Deemed dividend on warrant inducement offer | — | — | (1,360) | — |
| Deemed contribution on extinguishment of preferred stock | 740 | — | 740 | — |
| Net loss attributable to Catheter Precision, Inc. common stockholders | $(2,555) | $(5,109) | $(5,596) | $(9,154) |
| Net loss per share attributable to Catheter Precision, Inc. common stockholders, basic and diluted | $(0.92) | $(7.28) | $(2.26) | $(14.09) |
| Weighted-average common shares used in computing net loss per share, basic and diluted | 2,767,440 | 701,896 | 2,481,226 | 649,558 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.